BACKGROUND: Skull-base chondrosarcoma (ChSa) is a rare disease, and the prognostication of this disease entity is ill defined. METHODS: We assessed the long-term local control (LC) results, overall survival (OS), and prognostic factors of skull-base ChSa patients treated with pencil beam scanning proton therapy (PBS PT). Seventy-seven (male, 35; 46%) patients with histologically confirmed ChSa were treated at the Paul Scherrer Institute. Median age was 38.9 years (range, 10.2-70.0y). Median delivered dose was 70.0 GyRBE (range, 64.0-76.0 GyRBE). LC, OS, and toxicity-free survival (TFS) rates were calculated using the Kaplan Meier method. RESULTS: After a mean follow-up of 69.2 months (range, 4.6-190.8 mo), 6 local (7.8%) failures were observed, 2 of which were late failures. Five (6.5%) patients died. The actuarial 8-year LC and OS were 89.7% and 93.5%, respectively. Tumor volume > 25 cm(3) (P = .02), brainstem/optic apparatus compression at the time of PT (P = .04) and age >30 years (P = .08) were associated with lower rates of LC. High-grade (≥3) radiation-induced toxicity was observed in 6 (7.8%) patients. The 8-year high-grade TFS was 90.8%. A higher rate of high-grade toxicity was observed for older patients (P = .073), those with larger tumor volume (P = .069), and those treated with 5 weekly fractions (P = .069). CONCLUSIONS: This is the largest PT series reporting the outcome of patients with low-grade ChSa of the skull base treated with PBS only. Our data indicate that protons are both safe and effective. Tumor volume, brainstem/optic apparatus compression, and age were prognosticators of local failures.
BACKGROUND: Skull-base chondrosarcoma (ChSa) is a rare disease, and the prognostication of this disease entity is ill defined. METHODS: We assessed the long-term local control (LC) results, overall survival (OS), and prognostic factors of skull-base ChSa patients treated with pencil beam scanning proton therapy (PBS PT). Seventy-seven (male, 35; 46%) patients with histologically confirmed ChSa were treated at the Paul Scherrer Institute. Median age was 38.9 years (range, 10.2-70.0y). Median delivered dose was 70.0 GyRBE (range, 64.0-76.0 GyRBE). LC, OS, and toxicity-free survival (TFS) rates were calculated using the Kaplan Meier method. RESULTS: After a mean follow-up of 69.2 months (range, 4.6-190.8 mo), 6 local (7.8%) failures were observed, 2 of which were late failures. Five (6.5%) patients died. The actuarial 8-year LC and OS were 89.7% and 93.5%, respectively. Tumor volume > 25 cm(3) (P = .02), brainstem/optic apparatus compression at the time of PT (P = .04) and age >30 years (P = .08) were associated with lower rates of LC. High-grade (≥3) radiation-induced toxicity was observed in 6 (7.8%) patients. The 8-year high-grade TFS was 90.8%. A higher rate of high-grade toxicity was observed for older patients (P = .073), those with larger tumor volume (P = .069), and those treated with 5 weekly fractions (P = .069). CONCLUSIONS: This is the largest PT series reporting the outcome of patients with low-grade ChSa of the skull base treated with PBS only. Our data indicate that protons are both safe and effective. Tumor volume, brainstem/optic apparatus compression, and age were prognosticators of local failures.
Authors: Sei Young Lee; Young Chang Lim; Mee Hyun Song; Jae Yeon Seok; Won Sang Lee; Eun Chang Choi Journal: Yonsei Med J Date: 2005-04-30 Impact factor: 2.759
Authors: Thomas F DeLaney; Norbert J Liebsch; Frank X Pedlow; Judith Adams; Elizabeth A Weyman; Beow Y Yeap; Nicolas Depauw; G Petur Nielsen; David C Harmon; Sam S Yoon; Yen-Lin Chen; Joseph H Schwab; Francis J Hornicek Journal: J Surg Oncol Date: 2014-04-19 Impact factor: 3.454
Authors: A E Rosenberg; G P Nielsen; S B Keel; L G Renard; M M Fitzek; J E Munzenrider; N J Liebsch Journal: Am J Surg Pathol Date: 1999-11 Impact factor: 6.394
Authors: S Potluri; S J Jefferies; R Jena; F Harris; K E Burton; A T Prevost; N G Burnet Journal: Clin Oncol (R Coll Radiol) Date: 2010-10-25 Impact factor: 4.126
Authors: Bowen Jiang; Anand Veeravagu; Abdullah H Feroze; Marco Lee; Griffith R Harsh; Scott G Soltys; Iris C Gibbs; John R Adler; Steven D Chang Journal: J Neurooncol Date: 2013-06-08 Impact factor: 4.130
Authors: Damien C Weber; Alexei V Trofimov; Thomas F Delaney; Thomas Bortfeld Journal: Int J Radiat Oncol Biol Phys Date: 2004-04-01 Impact factor: 7.038
Authors: Hirotaka Hasegawa; Kunal Vakharia; Christopher S Graffeo; Matthew L Carlson; Bruce E Pollock; Paul D Brown; Avital Perry; Jamie J Van Gompel; Colin L W Driscoll; Michael J Link Journal: J Neurooncol Date: 2021-04-27 Impact factor: 4.130
Authors: Paolo Palmisciano; Ali S Haider; Mohammadmahdi Sabahi; Chibueze D Nwagwu; Othman Bin Alamer; Gianluca Scalia; Giuseppe E Umana; Aaron A Cohen-Gadol; Tarek Y El Ahmadieh; Kenny Yu; Omar N Pathmanaban Journal: Cancers (Basel) Date: 2021-11-26 Impact factor: 6.639